Iovance Biotherapeutics, Inc.
IOVA
$3.06
-$0.01-0.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 25.85% | 88.24% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 25.85% | 88.24% | |||
| Cost of Revenue | 14.36% | 26.95% | |||
| Gross Profit | 50.28% | 7,249.62% | |||
| SG&A Expenses | 7.46% | -0.04% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.57% | 10.98% | |||
| Operating Income | 2.80% | 12.61% | |||
| Income Before Tax | 9.48% | 13.70% | |||
| Income Tax Expenses | 202.50% | -4.25% | |||
| Earnings from Continuing Operations | 5.96% | 13.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.96% | 13.96% | |||
| EBIT | 2.80% | 12.61% | |||
| EBITDA | 3.04% | 13.85% | |||
| EPS Basic | 6.46% | 19.18% | |||
| Normalized Basic EPS | 6.73% | 18.96% | |||
| EPS Diluted | 6.46% | 19.18% | |||
| Normalized Diluted EPS | 6.73% | 18.96% | |||
| Average Basic Shares Outstanding | 0.53% | 6.48% | |||
| Average Diluted Shares Outstanding | 0.53% | 6.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||